Free Trial
OTCMKTS:APLIF

Appili Therapeutics (APLIF) Stock Price, News & Analysis

Appili Therapeutics logo
$0.01 +0.00 (+16.22%)
As of 05/27/2025 12:19 PM Eastern

About Appili Therapeutics Stock (OTCMKTS:APLIF)

Key Stats

Today's Range
$0.0129
$0.0144
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.04
Volume
600 shs
Average Volume
91,037 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Headlines

APLIF Stock Analysis - Frequently Asked Questions

Appili Therapeutics' stock was trading at $0.0280 at the beginning of the year. Since then, APLIF shares have decreased by 53.9% and is now trading at $0.0129.
View the best growth stocks for 2025 here
.

Appili Therapeutics Inc. (OTCMKTS:APLIF) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01).

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/13/2024
Today
5/28/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$630,000.00
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-0.26

Miscellaneous

Free Float
106,908,000
Market Cap
$1.56 million
Optionable
Not Optionable
Beta
-0.51
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (OTCMKTS:APLIF) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners